CN108703261A - Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease - Google Patents
Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease Download PDFInfo
- Publication number
- CN108703261A CN108703261A CN201810515018.3A CN201810515018A CN108703261A CN 108703261 A CN108703261 A CN 108703261A CN 201810515018 A CN201810515018 A CN 201810515018A CN 108703261 A CN108703261 A CN 108703261A
- Authority
- CN
- China
- Prior art keywords
- egg
- salmonella
- pharmaceutical composition
- laying hen
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 54
- 206010039438 Salmonella Infections Diseases 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 206010039447 salmonellosis Diseases 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 241000607142 Salmonella Species 0.000 claims abstract description 31
- 239000004471 Glycine Substances 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 230000009467 reduction Effects 0.000 claims abstract description 7
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 6
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 6
- 210000003278 egg shell Anatomy 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims description 8
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 2
- 229920002824 gallotannin Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 abstract description 30
- 230000036750 egg laying performance Effects 0.000 abstract description 6
- 230000005571 horizontal transmission Effects 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 238000006073 displacement reaction Methods 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 abstract description 2
- 208000037487 Endotoxemia Diseases 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 29
- 238000012360 testing method Methods 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 239000004576 sand Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006731 Salmonella Food Poisoning Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000994 inner shell membrane Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides pharmaceutical composition and is preparing prevention laying hen Salmonella infection disease, improving the application during Layer Production Performance, reduction eggshell and egg content carry detection of Salmonella quantity and improve the drug of laying hen Egg Quality, and each raw material medicaments in part by weight is calculated as in described pharmaceutical composition：20-50 parts of Chinese gallotanninic acid, 10-30 parts of glycine.The pharmaceutical composition that pharmaceutical composition of the present invention is prevented with the laying hen Salmonella infection disease that " origin conditioning " is core, have the characteristics that green safe, not tolerific, substitute antibiotics, it not only can effectively press down and kill detection of Salmonella, endotoxemia caused by eliminating thalline death release endotoxin, adjustable immunity of organism phylactic power defensive power simultaneously, purify laying hen detection of Salmonella, egg source contact scar caused by the horizontal transmission and potential endogenous displacement of reduction chicken group's detection of Salmonella, egg laying performance egg quality is improved, food-safety problem caused by the property detection of Salmonella of egg source is effectively avoided.
Description
Technical field
The invention belongs to veterinary drug technical fields, and in particular to pharmaceutical composition is preparing prevention laying hen Salmonella infection disease
Application in drug.
Background technology
The food-safety problem caused by food-borne causal agent increasingly obtains the attention of people, wherein detection of Salmonella
(Salmonella) food safety question caused by is the major reason that long-standing problem poultry industry develops in a healthy way.In U.S.
State, large-scale egg recall event become food security focus of attention again by the Salmonella infection of egg.Detection of Salmonella can
To infect egg by two kinds of approach of vertical transmission and horizontal transmission.The Salmonella infection caused by egg is considered as mankind's sense
One of the main reason for contaminating detection of Salmonella.Under normal conditions, old man, child and some to have the patient of immune deficiency to be easy infection husky
Door bacterium, shows as nausea,vomiting,diarrhea after infection, serious circulatory failure to occur and dead.There are about 3,700,000 every year in the U.S.
People infects detection of Salmonella, and the economic loss thereby resulted in is up to more than 6,400 ten thousand to 1 hundred million dollars.The infection of China's detection of Salmonella is also relatively tighter
Weight, is analyzed, between 20 years of 1983-2002, Shandong Province occurs Salmonella food poisoning 286 and rises altogether, in 11228 people according to investigations
Poison, 15 people are dead, and case fatality rate is up to 0.13%.
Currently, the control measure of salmonella gallinarum infectious disease mainly takes vaccine inoculation, monitoring to eliminate positive chicken and periodically throw
Large dosage of antibacterials are fed with temporary prevention effect.Vaccine inoculation is a kind of promising approach of control Salmonella infection, but by
Numerous in detection of Salmonella serotype, existing inactivated vaccine and Attenuate vaccine for particular serotype, Vaccine effectiveness is extremely limited, novel
Broad-spectrum high efficacy vaccine is still among research.Positive chicken is eliminated in monitoring, and purification chicken group's detection of Salmonella, economic cost is high, mostly in breeding public affairs
Department implements, and the latter is widely used in breeder breeding field and breeding layer chicken field, and the unreasonable use of antibiotic also results in detection of Salmonella
Drug tolerance of strain enhances, and Antibiotic Resistance is broadening.Studies have shown that from the sixties in last century begin, salmonella gallinarum to penicillin, streptomysin,
The drug resistance presentation of sulfa drugs, tetracycline, kanamycins and gentamicin etc. significantly increases variation tendency.Meanwhile state
Clear stipulaties laying cycle of laying hens antibiotic disabled list, a variety of common antibiotic must not be used for the chicken of laying period for family.
In July, 2017, exceeded containing Doxycycline and Florfenicol in the egg of two breeding layer chicken field of Nanyang, two chicken house fields are main by accordance with the law
It sentences.Therefore, it is to ensure laying hen industry health sane development to develop green safe, high-efficiency environment friendly substitute antibiotics new product
Strategic Demand.
Invention content
In order to solve the problems in the existing technology, the present invention provides it is a kind of safe and reliable, without hormone, without side-effects
And application of the pharmaceutical composition of medicament residue in preventing laying hen Salmonella infection disease, it can be used for purifying laying hen detection of Salmonella,
Egg source contact scar caused by the horizontal transmission and potential endogenous displacement of reduction chicken group's detection of Salmonella, improves egg quality, effectively keeps away
Food-safety problem caused by exempting from egg source property detection of Salmonella.
The present invention provides pharmaceutical composition and is preparing prevention laying hen Salmonella infection disease, improving Layer Production Performance, reduction
Eggshell and egg content carry detection of Salmonella quantity and improve the application in the drug of laying hen Egg Quality, in described pharmaceutical composition
Each raw material medicaments in part by weight is calculated as：20-50 parts of Chinese gallotanninic acid, 10-30 parts of glycine.
Preferably, each raw material medicaments in part by weight is calculated as in described pharmaceutical composition：30 parts of Chinese gallotanninic acid, glycine
20 parts.
Preferably, described pharmaceutical composition is to weigh Chinese gallotanninic acid and glycine according to recipe quantity, mixing to obtain the final product.
Preferably, the Layer Production Performance is laying rate, average egg weight and feedstuff-egg ratio.
Preferably, the raising laying hen Egg Quality is to improve shell thickness and reduction egg breakage rate.
When the pharmaceutical composition of the present invention is prepared into drug, excipient is usually added outside aforementioned pharmaceutical compositions, such as
Solid carrier, anticaking agent, mould inhibitor and corrigent etc., and powder, medicinal extract can be prepared into according to conventional formulation method
It is used after the dosage forms such as powders and granules.When being prepared into the drug of above-mentioned each dosage form, preparation preferably comprises 20- by weight
100% aforementioned pharmaceutical compositions are as active ingredient.
The example of solid carrier as excipient includes sucrose, glucolactone, dextrin etc..
Example as corrigent includes saccharin sodium, saccharin sodium, sodium glutamate etc..
For example the preparation process of drug is：According to prescription ratio, Chinese gallotanninic acid and glycine are weighed, adds auxiliary material, is made
It is dry at particle, whole grain to get.
Preferably, the auxiliary material includes sucrose and grape acid lactone, and the weight proportion of the two is 1：1.
The present invention is according to traditional veterinary drug theory and modern nutritional pharmacological principle, by effective component of chinese medicine and nutrient
It combines, forms the pharmaceutical composition prevented with the laying hen Salmonella infection disease that " origin conditioning " is core, have
Green safe, not tolerific feature.Wherein Chinese gall is common traditional Chinese medicine, has fall fire of astringing the lung, relieving diarrhea with astringents, holds back
Sweat hemostasis, hygroscopic sore and other effects.Tannic acid is gallic main pharmacodynamics material base, has antibacterial, antiviral, anti-parasitism
The pathogenic microorganisms such as worm activity.Meanwhile tannic acid has the multiple biological activities such as anti-oxidant, anti-inflammatory, immunological regulation.Glycine is
A kind of classificatory nonessential amino acid of nontraditional amino acid, in addition to conventional nutraceutical effect is outer, glycine have broad-spectrum antibacterial it is active,
Detection of Salmonella is killed in the multiple efficacies such as anti-endotoxin effect, anti-oxidation stress and immunological regulation, the two compatible use effectively suppression, and
Endotoxemia caused by eliminating thalline death release endotoxin, while the phylactic power defensive power of tested chicken can be effectively improved, purify egg
Salmonella gallinarum, egg source contact scar caused by the horizontal transmission and potential endogenous displacement of reduction chicken group's detection of Salmonella, improves egg productivity
Energy egg quality, effectively avoids food-safety problem caused by the property detection of Salmonella of egg source.
Specific implementation mode
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified city
It sells.
The pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention includes each component of following mass fraction：
20-50 parts of Chinese gallotanninic acid, 10-30 parts of glycine.
The tannic acid of the present invention is to extract from Chinese medicine Chinese gall, therefore claim Chinese gallotanninic acid.
The preparation method of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：In prescription ratio, weigh
Chinese gallotanninic acid and glycine, mixing is to get the pharmaceutical composition for preventing laying hen Salmonella infection disease.
Embodiment 1
The formula of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：
20 parts by weight of Chinese gallotanninic acid, 10 parts by weight of glycine.
According to prescription ratio, Chinese gallotanninic acid 20kg, glycine 10kg are weighed, mixing is to get for preventing laying hen sand
The pharmaceutical composition of door bacterium infectious disease.
Embodiment 2
The formula of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：
30 parts by weight of Chinese gallotanninic acid, 20 parts by weight of glycine.
According to prescription ratio, Chinese gallotanninic acid 30kg, glycine 20kg are weighed, mixing is to get for preventing laying hen sand
The pharmaceutical composition of door bacterium infectious disease.
Embodiment 3
The formula of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：
50 parts by weight of Chinese gallotanninic acid, 30 parts by weight of glycine.
According to prescription ratio, Chinese gallotanninic acid 50kg, glycine 30kg are weighed, mixing is to get for preventing laying hen sand
The pharmaceutical composition of door bacterium infectious disease.
Embodiment 4
The formula of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：
45 parts by weight of Chinese gallotanninic acid, 20 parts by weight of glycine.
According to prescription ratio, Chinese gallotanninic acid 45kg is weighed, glycine 20kg, mixing is to get for preventing laying hen sand
The pharmaceutical composition of door bacterium infectious disease.
Embodiment 5
The formula of pharmaceutical composition of the prevention laying hen Salmonella infection disease of the present invention is：
20 parts by weight of Chinese gallotanninic acid, 20 parts by weight of glycine.
According to prescription ratio, Chinese gallotanninic acid 20kg is weighed, glycine 20kg, mixing is to get for preventing laying hen sand
The pharmaceutical composition of door bacterium infectious disease.
Essence and pharmaceutical composition of the present invention in order to further illustrate the present invention prevents laying hen Salmonella infection disease
Advantageous effect, applicant have carried out Clinical Treatment Test research to pharmaceutical composition of the present invention, to illustrate pharmaceutical composition of the present invention
The excellent effect of object.
Embodiment 6
(1) the evaluation of clinical curative effect experimental study of medicine composite for curing laying hen Salmonella infection disease of the present invention
1 test drug
Pharmaceutical composition of the present invention.
2 experimental animals
The salmonella gallinarum antibody positive chicken group of Hebei Cangzhou breeding layer chicken field, this laying rate of laying hen and rate of fertilization compared with
Low, dead germ rate is higher, and sramana is detected as using white diarrhea, fowl typhoid multivalence Avian tubercula plain agglutination test antigen (China Veterinary Drugs Supervisory Inst.'s production)
The chicken of the bacteria antibody positive is included in this experimental study, shares 400, is egg-laying peak chicken.
3 experimental designs
The above-mentioned salmonella gallinarum antibody positive laying hen for meeting this research is randomly divided into 4 groups by 3.1 random groupings, wherein compareing
Group (100), 3 groups of experiment 1 group (embodiment 1,100), experiment 2 groups (embodiments 2,100) and experiment (embodiments 3,100
Only).
3.2 therapeutic schemes pharmaceutical composition group of the present invention (3 groups of 1 group of experiment, 2 groups of experiment and experiment), according to 0.1g/kg
Bw dosages are used in conjunction 7 days once a day.Control group, amoxicillin soluble powder, a secondary amounts, per 1kg weight 30mg,
2 times a day, it is used in conjunction 7.
3.3 efficacy determinations and detection method
3.3.1 index of assessment of curative effect
The 14th day after effective last medication treatment, sramana's bacteria antibody is detected using blood plate agglutination test, the person of turning out cloudy sentences
It is effective.
The 14th day after invalid last medication treatment, sramana's bacteria antibody is detected using blood plate agglutination test, is positive
It is invalid to be judged to.
3.3.2 after detection method fully shakes up white diarrhea, fowl typhoid multivalence Avian tubercula plain agglutination test antigen, 20 are drawn with pipettor
Then μ l drops puncture vein under chicken wings on glass plate with syringe needle, after blood outflow, draw 20 μ l blood with pipettor immediately
It is put into antigen liquid, blood is uniformly mixed with antigen, and it is about 2cm so that it is scattered to diameter, gently shakes reaction plate, carefully
Observation, judges result in 2min.It is the positive apparent particle or blocky agglutination person occur, and it is the moon that particle or agglutination person do not occur
Property, between it is above-mentioned be between the two it is suspicious, after 7 days acquiring blood again is detected confirmation.
4 data statistics
It utilizes(Version 17.0) carries out data analysis.The healing of four groups of tested chickens is evaluated in Chi-square Test
Rate, P<0.05 thinks that the difference examined is statistically significant.
5 results
Compared with the control group, the cure rate pole of medicine composite for curing laying hen Salmonella infection disease of the present invention significantly improves (p
<0.01), three other cure rates of group are respectively 85.0%, 95.0% and 93.0%, the results are shown in Table 1.
1 medicine composite for curing laying hen Salmonella infection disease clinical effect trial result of the present invention of table
Note：Same letter person difference not significantly (P> is indicated with column data shoulder;0.05) different lowercase person differences, are marked
Significantly (P<0.05)；Same group same column marks different capitalization person significant difference (P<0.01).Similarly hereinafter.
6 conclusions
Pharmaceutical composition of the present invention can effectively treat laying hen Salmonella infection disease.Since the pharmaceutical composition of embodiment 2 exists
Therapeutic effect is best in curative tests result, pretends the test medicine of the clinical test to prevent laying hen Salmonella infection disease.
(2) pharmaceutical composition of the present invention prevents the clinical effectiveness of laying hen salmonella gallinarum infection
1 test drug
The pharmaceutical composition of the present invention of embodiment 2.
2 experimental animals
Hebei Cangzhou breeding layer chicken field, totally 5000 laying hens, 28 week old, average weight are 3.7 ± 0.3kg/.
3 purification schemes
It is not divided into control group (2300) and purification administration group (2700) according to, starts to purify medication in 28 week old,
According to 0.1g/kgbw dosages, it is administered 7 days, it is as a treatment course, later at interval of one course for the treatment of of medication in 30 days, until
58 week old are eliminated, and are shared medicine and are intervened 28 weeks.And control group is not administered, two groups are in henhouse structure, cage tool, feed, drinking-water, illumination
With it is completely the same on immune equal feeding and management conditions.
4 test indexes are observed and record
4.1 detection of Salmonella antibody positive rates be detected on administration before (the 28th week), the 40th week and 52 weeks, using blood tablet agglutination
Testing inspection salmonella gallinarum antibody positive rate.Method is same as above.
The influence of the production performance of 4.2 pairs of tested chickens
4.2.1 egg laying performance
Laying rate：It is the every day entry egg production of unit to repeat (cage), counts laying rate.Laying rate=100 × egg production
(piece)/chicken number (only).
Average egg weight：To repeat (cage) as unit, weigh daily by piece.
Average daily gain：It using " knock-out bottom " method, to repeat (cage) as unit, counts 1 time weekly, when off-test counts
Calculate full period average daily gain.
Feedstuff-egg ratio：To repeat (cage) as unit, feedstuff-egg ratio is calculated by experimental period total egg production and feed consumption：Feedstuff-egg ratio
Food consumption total amount (kg)/often is often repeated during=measurement repeats total yield egg size (kg).
4.2.2 egg detection of Salmonella
It is carried out with reference to 4789.4-2010 microbiological test of food hygiene detection of Salmonella of GB/T.Using preceding increasing bacterium, increase bacterium pair
Detection of Salmonella is expanded, and separation bacterium pure culture is inoculated in respectively in Bacteria Identification culture medium and micro biochemical reaction tube, is set
36 DEG C of constant temperature incubations 18~for 24 hours, observing response situation, then identified.
4.2.3 egg quality
(cage) during experiment, is often repeated weekly and randomly selects 7 pieces of egg, measures following index respectively：
Egg proportion：It is measured with saline floatation method.
Egg shape index：The major diameter and minor axis of vernier caliper measurement egg calculate egg shape index.Egg shape index=major diameter/minor axis.
Shell thickness：Take respectively blunt end, middle part, sharp end eggshell reject inner shell membrane after with miking, its thickness asks flat
Mean value.As unit of mm, it is accurate to 0.01mm.
Egg breakage rate：The ratio of damaged egg number and total egg number.
5 data processings
It utilizes(Version 17.0) carries out data analysis.All statistical checks are all made of two-sided test, p<
0.05 thinks that the difference examined is statistically significant.
6 pharmaceutical compositions of the present invention prevent the clinical effectiveness of laying hen Salmonella infection disease
6.1 pharmaceutical compositions of the present invention prevent the effect of laying hen Salmonella infection disease
Compared with the control group, before experiment, salmonella gallinarum antibody positive rate indifference (p > 0.05) in two groups；40th week and
52nd week, laying hen detection of Salmonella antibody positive rate pole significantly reduced (p< in pharmaceutical composition of the present invention;0.01).It the results are shown in Table 2.
2 pharmaceutical composition of the present invention of table purifies the clinical effect trial result of laying hen Salmonella infection disease
Influence of 6.2 pharmaceutical compositions of the present invention to the egg laying performance of tested chicken group
Compared with the control group, the average daily gain indifference (p > 0.05) of tested chicken group, and laying rate, average egg weight
It is improved with feedstuff-egg ratio, significant difference (p<0.05).Show to bestow method and purification scheme according to pharmaceutical composition of the present invention, can have
Effect improves the egg laying performance of tested laying hen group, the results are shown in Table 3.
Influence of 3 pharmaceutical composition of the present invention of table to the egg laying performance of tested chicken group
6.3 pharmaceutical compositions of the present invention carry the egg of tested chicken group the influence of detection of Salmonella
Compared with the control group, the egg eggshell of tested chicken group and egg content detection of Salmonella recall rate reduce, and difference is extremely notable
(p<0.01).It the results are shown in Table 4.
4 pharmaceutical composition of the present invention of table carries the egg of tested chicken group the influence of detection of Salmonella
Influence of 6.4 pharmaceutical compositions of the present invention to the Egg Quality of tested chicken group
Compared with the control group, the egg proportion and egg shape index indifference (p > 0.05) of the egg of tested chicken group, and eggshell
Thickness significantly improves (p<0.05) and egg breakage rate pole significantly reduces (p<0.01).It the results are shown in Table 5.
Influence of 5 pharmaceutical composition of the present invention of table to the Egg Quality of tested chicken group
| Group | Egg proportion | Egg shape index | Shell thickness | Egg breakage rate % |
| Control group | 1.08 | 1.28±0.01 | 0.35±0.02a | 2.2A |
| Test group | 1.08 | 1.27±0.01 | 0.37±0.01b | 0.3B |
7 conclusions bestow method according to pharmaceutical composition of the present invention and prevent intervention stratege, and it is husky can effectively to reduce tested chicken group
Door bacteria antibody positive rate, improves egg laying performance, reduces egg detection of Salmonella carrying rate, improves egg quality.
Finally it should be noted that：The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
With technical scheme described in the above embodiments is modified or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in the present invention's
Within protection domain.
Claims (5)
1. pharmaceutical composition is preparing prevention laying hen Salmonella infection disease, is improving Layer Production Performance, reduction eggshell and egg content
Object carries the application in the drug of detection of Salmonella quantity and raising laying hen Egg Quality, and each bulk pharmaceutical chemicals are by weight in described pharmaceutical composition
Amount part is calculated as：20-50 parts of Chinese gallotanninic acid, 10-30 parts of glycine.
2. application according to claim 1, it is characterised in that：Each raw material medicaments in part by weight meter in described pharmaceutical composition
For：30 parts of Chinese gallotanninic acid, 20 parts of glycine.
3. application according to claim 1 or 2, it is characterised in that：Described pharmaceutical composition is to weigh five according to recipe quantity
Gallotannin acid and glycine, mixing to obtain the final product.
4. application according to claim 1, it is characterised in that：The Layer Production Performance be laying rate, average egg weight and
Feedstuff-egg ratio.
5. application according to claim 1, it is characterised in that：The raising laying hen Egg Quality is to improve shell thickness and drop
Low egg breakage rate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810515018.3A CN108703261A (en) | 2018-05-25 | 2018-05-25 | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810515018.3A CN108703261A (en) | 2018-05-25 | 2018-05-25 | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108703261A true CN108703261A (en) | 2018-10-26 |
Family
ID=63869581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810515018.3A Pending CN108703261A (en) | 2018-05-25 | 2018-05-25 | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108703261A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108771703A (en) * | 2018-05-17 | 2018-11-09 | 中国农业科学院兰州畜牧与兽药研究所 | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106721026A (en) * | 2017-01-05 | 2017-05-31 | 辽宁禾丰牧业股份有限公司 | A kind of nonreactive laying cycle of laying hens compound premixed feed and preparation method and application |
| CN107027973A (en) * | 2017-05-25 | 2017-08-11 | 广州汇加生物科技有限公司 | A kind of tannin mixture for reducing or eliminating vegatable tannin astringent taste and preparation method and application |
-
2018
- 2018-05-25 CN CN201810515018.3A patent/CN108703261A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106721026A (en) * | 2017-01-05 | 2017-05-31 | 辽宁禾丰牧业股份有限公司 | A kind of nonreactive laying cycle of laying hens compound premixed feed and preparation method and application |
| CN107027973A (en) * | 2017-05-25 | 2017-08-11 | 广州汇加生物科技有限公司 | A kind of tannin mixture for reducing or eliminating vegatable tannin astringent taste and preparation method and application |
Non-Patent Citations (6)
| Title |
|---|
| 侯海锋，等: "水解单宁酸对蛋鸡生产性能和鸡舍中氨气含量的影响", 《今日畜牧兽医》 * |
| 李松龄，等: "《畜牧兽医实用新技术》", 31 March 2009, 中原农民出版社 * |
| 段久芳: "《天然高分子材料》", 30 September 2016, 华中科技大学出版社 * |
| 蒲万霞，等: "《生态土鸡健康养殖技术》", 30 June 2017, 甘肃科学技术出版社 * |
| 韩德五，等: "《肠源性内毒素血症与肝病 肝衰竭的IETM学说》", 31 March 2004, 中国科学技术出版社 * |
| 魏昆鹏，等: "水解单宁酸对家禽肠道健康的促进作用", 《中国动物保健》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108771703A (en) * | 2018-05-17 | 2018-11-09 | 中国农业科学院兰州畜牧与兽药研究所 | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease |
| CN108771703B (en) * | 2018-05-17 | 2021-05-04 | 中国农业科学院兰州畜牧与兽药研究所 | Application of pharmaceutical composition in preparation of drugs for preventing and treating salmonellosis infection of laying hens |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023284848A1 (en) | Fructooligosaccharide having high kestose content and application thereof | |
| CN108703261A (en) | Application of the pharmaceutical composition in the drug for preparing prevention laying hen Salmonella infection disease | |
| CN101085037B (en) | Traditional Chinese medicine preparation for animals and preparation method thereof | |
| CN105012946A (en) | Pasteurellosis and duck colibacilosis combined propolis inactivated vaccine and preparation method thereof | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| CN110946862B (en) | Application of sanguinarine in inhibition of growth of multiple drug-resistant enterobacter hopcalis | |
| CN108653300B (en) | Pharmaceutical composition for purifying seed of salmonella gallinarum | |
| CN105748861B (en) | Anti-stress traditional Chinese medicine composition, preparation method and application thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN108771703B (en) | Application of pharmaceutical composition in preparation of drugs for preventing and treating salmonellosis infection of laying hens | |
| CN109432106B (en) | Compound sulfachlorpyridazine and preparation method thereof | |
| CN108452014B (en) | Pharmaceutical composition for purifying seed of salmonella gallinarum | |
| CN101780064B (en) | New application of p-hydroxyl cinnamic acid | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN109394881A (en) | Prevent and treat pure Chinese medicine composition of poultry enterotoxin syndrome and preparation method thereof and application method | |
| CN114306416B (en) | Astragalus polysaccharide complex and its application in antibiosis and immunity enhancement | |
| CN113694096B (en) | Licorice extract and preparation method and application thereof | |
| RU2505305C1 (en) | Method of treating respiratory diseases of calfs | |
| CN113499328B (en) | Application of licochalcone A in preparation of drugs for resisting clostridium difficile infection | |
| CN102068536B (en) | Compound Chinese medicinal particles and application thereof in preparation of medicament for preventing and treating pig digestive tract disease | |
| CN102293764A (en) | New application of p-hydroxycinnamic acid | |
| CN102940707A (en) | Medicine composition for preventing and treating chicken coccidiosis, premix and batch | |
| CN104208049A (en) | Application of bronopol and analogue thereof in drug preparation | |
| CN113599398A (en) | Pharmaceutical composition for preventing and treating calf intestinal colibacillosis and preparation method thereof | |
| CN112843096A (en) | Application of clostridium butyricum in preparation of preparation for treating coronavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181026 |